Rivia Secures €13M to Supercharge Clinical Trials with Agentic AI

business #agent 📝 Blog|Analyzed: Mar 18, 2026 10:47•

Published: Mar 18, 2026 09:40

•

1 min read

Analysis

Rivia is making waves by utilizing agentic AI to revolutionize clinical trials, a notoriously complex and inefficient field. This funding injection will allow them to build AI agents capable of actively managing the intricate operational layer of these trials, promising a more streamlined and effective approach. The potential for improved data management and faster results is truly exciting!

Key Takeaways

•Rivia raised €13 million to develop AI agents.
•The agents will manage clinical trial operations.
•This aims to streamline the information-intensive processes of medical research.

Reference / Citation

View Original

"The Zurich-based startup... has secured a larger round to build AI agents that actively manage the complex operational layer of running a clinical trial."

The Next WebMar 18, 2026 09:40

* Cited for critical analysis under Article 32.

Older

GV's Tom Hulme on AI's Bright Future: Investment Opportunities & Innovation

Newer

Proofpoint Unveils AI Security Platform to Safeguard AI Agents